Stage 4 adenocarcinoma non-small cell (aNSCLC) lung cancer treatment has been dictated in recent years by the genetic mutation, or biomarker. Patients received either chemotherapy, immunotherapy, a combination of the two, or a personalized targeted therapy depending on the [...]
For several years stage 4 adenocarcinoma non-small cell (aNSCLC) lung cancer treatment has been dictated by the genetic mutation, called biomarkers, of the patient. A patient’s treatment was seen as either chemotherapy, immunotherapy (or some sort of combination of [...]
Increasing diversity within lung cancer clinical trials is of critical importance for patients, caregivers, and researchers. To make sure that you are informed and prepared to share the message, we’ve pulled together some helpful blog posts and downloadable materials [...]
Innovative effort aims to improve outcomes for historically underserved lung cancer patient community. SAN CARLOS, Calif. and WASHINGTON, D.C., May 11, 2021 – GO2 for Lung Cancer (GO2 for Lung Cancer) has launched a landmark initiative to identify the [...]
Daniel A. Saez, M.Sc., Treatment and Trials Navigator Guiding patients to clinical trials and other treatment options. Daniel Saez is the voice of LungMATCH. He’s the person you hear and the navigator you’re most likely to talk [...]
By Rashmi Acharya, MS, Coordinator, Science & Research, GO2 for Lung Cancer 1. What is Small Cell Lung Cancer? Small cell lung cancer (SCLC) is a type of lung cancer named for the very small, oval shaped cancer cells [...]
By Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer Rebecca (KRAS driven stage 4 NSCLC patient) and Wayne Yeung (caregiver) Since the original publication of this article, the United States Food [...]
It may seem like clinical trials are suddenly top of mind here at GO2 for Lung Cancer, with new articles about inclusive research and demystifying them with a brand-new FAQ. But clinical trials and the diversity of the patients within [...]
SAN CARLOS, Calif. and WASHINGTON – GO2 for Lung Cancer (GO2 for Lung Cancer) announced its leadership in the launch of an important multi-institutional study to determine how to improve the participation of Black communities in lung cancer clinical [...]
By Jennifer C. King, Ph.D., Chief Scientific Officer, GO2 for Lung Cancer Are scientists learning enough about how people just like you respond to new treatments? You may be surprised. Clinical trial participation rates among people with cancer in the [...]